Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy

被引:11
作者
Matsumura, Yoshihisa [1 ]
Hoshikawa-Nagai, Eri [2 ]
Kubo, Toru [2 ]
Yamasaki, Naohito [2 ]
Kitaoka, Hiroaki [2 ]
Takata, Jun [3 ]
Doi, Yoshinori [4 ]
Sugiura, Tetsuro [1 ]
机构
[1] Kochi Univ, Kochi Med Sch, Dept Lab Med, Kochi, Oko Cho 7838505, Japan
[2] Kochi Univ, Kochi Med Sch, Dept Cardiol Neurol & Aging Sci, Kochi, Oko Cho 7838505, Japan
[3] Kochi Univ, Kochi Med Sch, Ctr Promote Creat Med Educ, Kochi, Oko Cho 7838505, Japan
[4] Chikamori Hosp, Kochi, Japan
基金
日本学术振兴会;
关键词
Remodeling; Atrial fibrillation; Cardiomyopathy; Heart failure; CHRONIC HEART-FAILURE; CLINICAL-OUTCOMES; EJECTION FRACTION; IMPROVEMENT; PROGNOSIS; ECHOCARDIOGRAPHY; CONJUNCTION; TACHYCARDIA; PREVALENCE; RECOVERY;
D O I
10.1186/s12947-015-0009-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Predictors of left ventricular reverse remodeling (LVRR) after therapy with angiotensin converting enzyme inhibitors or angiotensin-receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy (IDC) remains unclear. Methods: We studied 44 patients with IDC who had been treated with the therapy. LVRR was defined as LV end-diastolic dimension <= 55 mm and fractional shortening >= 25% at the last echocardiogram. Results: During a mean follow-up period of 4.7 +/- 3.3 years, LVRR occurred in 34% (15/44) of the patients. We divided the patients into 2 groups: (1) patients with LVRR (n = 15); (2) patients without LVRR (n = 29). The presence of atrial fibrillation was 40% in patients with LVRR and 14% in those without (p = 0.067). Initial LV end-diastolic dimension was significantly smaller (62 +/- 6 vs. 67 +/- 6 mm, p = 0.033) in patients with LVRR than in those without. Initial LV end-diastolic dimension of 63.5 mm was an optimal cutoff value for predicting LVRR (sensitivity: 67%, specificity: 59%, area under the curve: 0.70, p = 0.030). When patients were further allocated according to initial LV end-diastolic dimension <= 63.5 mm with atrial fibrillation, the combined parameter was a significant predictor of LVRR by univariate logistic regression analysis (odds ratio, 5.78, p = 0.030) (sensitivity: 33%, specificity: 97%, p = 0.013). Conclusions: Combined information on LV end-diastolic dimension and heart rhythm at diagnosis is useful in predicting future LVRR in patients with IDC.
引用
收藏
页数:6
相关论文
共 50 条
[21]   Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: A review of the current evidence [J].
Tsouli, SG ;
Liberopoulos, EN ;
Kiortsis, DN ;
Mikhailidis, DP ;
Elisaf, MS .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2006, 11 (01) :1-15
[22]   Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation [J].
Anis, Rafik R. .
EXPERIMENTAL & CLINICAL CARDIOLOGY, 2009, 14 (01) :E1-E7
[23]   Perioperative management of patients treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a quality improvement audit [J].
Vijay, A. ;
Grover, A. ;
Coulson, T. G. ;
Myles, P. S. .
ANAESTHESIA AND INTENSIVE CARE, 2016, 44 (03) :346-352
[24]   Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients [J].
Kido, Ryo ;
Akizawa, Tadao ;
Fukagawa, Masafumi ;
Onishi, Yoshihiro ;
Yamaguchi, Takuhiro ;
Fukuhara, Shunichi .
AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (06) :439-447
[25]   Pharmacotherapy for heart failure with left ventricular dysfunction:: Beyond angiotensin-converting enzyme inhibitors and β-blockers [J].
Norgard, Nicholas B. ;
Stark, Jennifer E. .
PHARMACOTHERAPY, 2008, 28 (07) :920-931
[26]   Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers After Transcatheter Aortic Valve Replacement A Meta-Analysis [J].
Bhat, Vivek ;
Kumar, Ashish ;
Kalra, Ankur .
JACC-ADVANCES, 2024, 3 (05)
[27]   From Evidence to Rationale: Cardiovascular Protection by Angiotensin II Receptor Blockers Compared with Angiotensin-Converting Enzyme Inhibitors [J].
Boehm, Michael ;
Baumhaekel, Magnus ;
Mahfoud, Felix ;
Werner, Christian .
CARDIOLOGY, 2010, 117 (03) :163-173
[28]   Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers [J].
Walfisch, A. ;
Al-maawali, A. ;
Moretti, M. E. ;
Nickel, C. ;
Koren, G. .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2011, 31 (06) :465-472
[29]   Angiotensin-receptor blockers in prevention of cardiovascular events: are they as effective as angiotensin-converting enzyme inhibitors? [J].
Teo, Koon K. .
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2009, 119 (1-2) :8-10
[30]   Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure [J].
Chitnis, Abhishek S. ;
Aparasu, Rajender R. ;
Chen, Hua ;
Kunik, Mark E. ;
Schulz, Paul E. ;
Johnson, Michael L. .
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2016, 31 (05) :395-404